Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sarepta Wins Exon 51 Composition Patent Rights Over BioMarin

Executive Summary

Patent Trial and Appeal Board rules against BioMarin in proceeding to determine who has rights to a composition of matter patent for eteplirsen; last year the board ruled in BioMarin's favor on method of use patent.

Advertisement

Related Content

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119176

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel